Compare Inovio Pharmaceuticals Inc (INO) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Mercadolibre Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Mercadolibre Inc trades at $1,802.15 (market cap $92.90B). The key difference: Mercadolibre Inc is far larger — about 1040.7× Inovio Pharmaceuticals Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MELI | |
|---|---|---|
Market Cap | $89.27M | $92.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $2.51K |
52-Week Low | $1.05 | $1.55K |
Enterprise Value | $60.28M | $99.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MercadoLibre (MELI) trades at $1,832.29, up 1.01% in the last session, while showing a bearish technical signal overall. The company reported strong revenue growth, with 2025 revenue reaching $28.89 billion, though recent quarterly EPS results have missed expectations. Operating cash flow improved significantly to $12.12 billion in 2025, and analyst sentiment remains strongly positive with a consensus price target of $2,230.
The outlook for MELI is supported by robust top-line expansion and strategic investments in logistics and fintech, but near-term margin pressure and recent earnings misses present risks. The stock offers growth potential in Latin American e-commerce and digital payments, balanced by competitive and execution challenges in a dynamic market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
